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This 12-chapter-book, written by neurogeneticist Rudolph E.
Tanzi and science journalist Ann B. Parson, illustrates the rev-
olution, during the past two decades of the past century, in
research on Alzheimer disease (AD). This revolution was
strongly influenced by creative and enthusiastic scientists such
as Tanzi, one of the early protagonists of molecular neuro-
genetics. During his search for a longer-lasting perspective for
his future, a job posting came to the attention of the young
rock musician Tanzi. That’s how he found, in 1980, his first
position, as a technician in the lab of James Gusella, a visionary
neuroscientist. Already, at this early stage, Gusella was con-
vinced that it would be possible to track down, through mo-
lecular linkage analysis, the gene for Huntington disease (HD).
The reader learns about “repetitive-motion syndrome” (p. 16),
caused by the hard and monotonous work of transforming
and growing lymphocytes from hundreds of study subjects to
genotype RFLPs by classic Southern blotting. This strategy had
an unexpectedly early success, and results were published, in
1983, in a seminal paper, coauthored by Tanzi, on the chro-
mosomal localization of HD. Motivated by this experience,
Tanzi felt challenged to find a genomic locus for AD. Devoted
to neurogenetics and equipped with his skills and his trust in
molecular genetics’s “cookbook” science (p. 63), he joined the
field of neuroscience, where, as a graduate student, he achieved
notable success. The authors describe historic milestones in
AD research that have contributed to the slow process of rec-
ognizing that dementia is a disease (most often, AD) but is not
an obligatory sign of aging. Major contributions of some of
the leading scientists in the field of AD research—particularly
those crossing Tanzi’s pathways in the United States—are de-
scribed in more detail, along with anecdotes telling us about
their friendships, rivalries, hopes, fears, and jealousies, thereby
giving an interesting insight into some facets of this highly
competitive field as well as into Tanzi’s personal view of those
aspects of their interaction. The authors describe an insider’s
perspective on the findings and circumstances that led to the
discovery of four genes (APP, APOE, PSEN1, and PSEN2) of
major importance in today’s experimental research on AD. In
the final pages of Decoding Darkness, Tanzi takes the oppor-
tunity to defend his group’s association studies of a2 mac-
roglobulin (A2M), a candidate gene for AD. The authors are
very optimistic that further progress will be made, in the near
future, in the identification of both other risk alleles of can-
didate genes for AD and new drugs for efficient treatment of
AD.
Essential terms and basic principles of molecular genetics,
alongside figures, are introduced to the lay reader. Therefore,
the book may be an informative and entertaining lesson for
scientists, physicians, students, and the lay public interested in
this field.
Decoding Darkness tells about the great successes of mo-
lecular-genetics research in AD, most often a multifactorial
disease. Many other multifactorial diseases are still awaiting
such key discoveries. Meanwhile, autosomal dominant familial
AD (FAD) is one of the several hundred rare Mendelian dis-
orders that are the subjects of continuing genetic counseling
and, possibly, of molecular diagnostics. Most likely, !1% of
all cases of AD that occur worldwide are caused by FAD-
related mutations in APP, in PSEN1, in PSEN2, or in yet-
unknown genes. In whites, APOE’s allelic variant e4 seems to
be responsible for 10%–20% of all cases of AD (a percentage
that may increase with life expectancy). Similar to other areas
in neuropsychiatric genetics, the search for additional risk al-
leles in candidate genes of AD is characterized by an endless
series of discoveries followed, sooner or later, by nonconfir-
matory findings (usually reported in lower-impact journals).
In spite of distinct breakthroughs in genetic research on AD,
the proportion of cases of AD attributable to genetic factors
remains unknown. Until now, the new molecular insights fa-
cilitated by genetic discoveries have left us with unresolved
paradoxes (Checler 2001) requiring further intense research,
both for an understanding of the molecular cascade causing
AD and for the development of novel therapies. In conclusion,
this book—and its authors’ optimism—may give the lay public
(1) incorrect perceptions about the impact that genes have on
AD and (2) unwarranted expectations about the therapeutic
potential of next-generation drugs.
ULRICH FINCKH
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